Press Releases

Immunomodulatory Formula Offered as Prospective Ebola Therapeutic

The Demonstrated Antiviral Activity of Calcium Folate Makes ImmunoPterin™ a Good Candidate for the Treatment of This Viral Epidemic.

San Diego, CA, August 20, 2014 --(PR.com)-- Today, SanRx®, has announced that it’s immune support supplement product ImmunoPterin™ has demonstrated efficacy against symptoms similar to those effecting early Ebola sufferers. Ebola acts by defeating immune defenses in the body early in infection. The pterin-based compounds found in ImmunoPterin™ have been shown to suggest a strong ability to boost the human immune system against a number of other disease conditions, including cancerous tumors, Hepatitis B, Tuberculosis and Diabetes.

President & Chief Scientist Dr. Phillip Moheno of SanRx® stated, “With the call of ‘All hands on deck’ by the Center for Disease Control to confront the growing Ebola virus epidemic, SanRx Pharmaceuticals, Inc, has responded by offering up its immunomodulatory formulation, calcium folate as an prospective therapeutic. Calcium folate has already demonstrated efficacy against influenza. Early Ebola symptoms are similar to those of influenza. Both viral infections are characterized by modulations of the pro-inflammatory cytokine IL-6, and other cytokines. IL-6 has been shown to be modulated by calcium pterin, similar in structure to calcium folate which is more potent. Lower doses of calcium folate are anti-inflammatory and therefore advised. The demonstrated antiviral activity of calcium folate makes it a good candidate for the treatment of Ebola.”

The Ebola outbreak in West Africa has brought increased attention to the deadly virus. According to the World Health Organization, up to 90% of those infected with Ebola die from the virus. In an article recently published by Huffington Post, Dr. Gaya Amarasinghe is quoted stating, "what makes Ebola virus different is that it attacks a body's immune system on multiple fronts. There are different treatment windows for each modality, so having multiple methods would be really beneficial, depending on the type of outbreak."

SanRx Publishes Positive Results Against TB with Pterin-Based DCP

FOR IMMEDIATE RELEASE - San Diego – April 9, 2013 – SanRx (http://www.sanrx.com/) announced today the acceptance of its manuscript detailing the positive results obtained with its patented dipterinyl calcium pentahydrate (DCP) compound against Tuberculosis. The paper, "Dipterinyl Calcium Pentahydrate inhibits intracellular mycobacterial growth in human monocytes via the C-C chemokine MIP-1β and Nitric Oxide" describes how the anti-tuberculosis effect of DCP operates through specific immunological pathways. The work, carried out at the Division of Infectious Diseases, Allergy & Immunology, Edward A. Doisy Research Center, Saint Louis University School of Medicine, will be published by the American Society for Microbiology in their journal Infection and Immunity. The manuscript is available online prior to print at http://www.sanrx.com/science/publications/.

“Tuberculosis remains one of the top three leading causes of morbidity and mortality worldwide, complicated by the emergence of multiple drug-resistant mycobacterium tuberculosis strains and high rates of HIV co-infection,” stated Dr. Phillip Moheno, SanRx President and Founder and co-author of the paper. “In this study we tested the ability of DCP to inhibit the growth of tuberculosis and related mycobacteria within human monocytes (important immune cells involved in countering tuberculosis), and achieved significantly positive results,” added Moheno.
 
According to the Center for Disease Control and Prevention, http://www.cdc.gov/tb, Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis. The bacteria usually attack the lungs, and if not treated properly, TB can be fatal.

“The results indicate that the antimicrobial activity of DCP is comparable to that of pyrazinamide (PZA), one of the first-line anti-tuberculosis drugs currently used. Additionally, since DCP acts by strengthening the immune system, it will likely reinforce the effects of other TB drugs when used in combination,” Moheno commented.

“Dipterinyl calcium pentahydrate (DCP) breaks down into calcium pterin (API – active pharmaceutical ingredient) upon ingestion, as does the SanRx dietary supplement ImmunoPterin (http://www.sanrx.com/products/#ImmunoPterin), leading us to believe ImmunoPterin will have similar anti-mycobacterial efficacy as DCP, with no significant side effects,” added Moheno. Clinical trials are planned.

About SanRx

Based in San Diego, California, SanRx® is the leading developer of immune-supporting compounds based on the naturally-occurring human small molecule "pterin." Preclinical testing by reputable third-party laboratories substantiates that the compounds discovered by SanRx provide a strong potential to support the human immune system against a number of immune imbalance conditions without the side effects or high cost of traditional therapies.
For more information, visit www.sanrx.com.

Company Contact:
Dr Phillip Moheno, SanRx President and Chief Scientist,
phil.moheno@sanrx.com, 858-344-9778.

Media Contact:
Cynthia Jones, Jones & Taylor Communications,
cj@sanrx.com 928-273-0513.





Previous Press Releases

SanRx® Introduces ImmunoPterin™ – Potent Supplement for
Immune System Support Based on Pterins

SAN DIEGO – December 17, 2012

San Diego-based nutraceutical startup SanRx announced today the introduction of its first immune support supplement product – ImmunoPterin™. Based on independent laboratory analyses, the patent-pending, proprietary blend of calcium chloride and folic acid in ImmunoPterin makes it the only known supplement specifically designed to produce pterins – potent, naturally occurring immune supporting compounds. "ImmunoPterin is a different approach to immune support, targeting IDO, a chemical reaction in the body that inhibits immunity," stated Dr. Phillip Moheno, SanRx President and Chief Scientist.

"Pterins have the ability to inhibit IDO, potentially allowing the body to fend off immune imbalances of all kinds, from diabetes and cancer to the common cold," added Moheno. "We are steadily receiving testimonials from people who have been taking ImmunoPterin that it is having a positive impact on their health."

SanRx scientists have spent over 40 years researching the potential immune imbalance-fighting properties of pterins, a naturally occurring human small molecule. From this extensive research both pharmaceutical (DCP™) and nutraceutical (Pterin+Calcium™) solutions emerged, requiring extensive and expensive FDA testing. "Through evaluating preliminary third-party test results, we concluded ImmunoPterin could provide the same immune imbalance fighting benefits in a supplement, allowing immediate availability," commented Moheno.

According to Moheno, ImmunoPterin is the only supplement specifically designed to produce immune-supporting pterins, which have been shown in preclinical research to arm the immune system against several immune imbalances. ImmunoPterin's patent pending formulation is stomach friendly, with no known interactions and features enhanced calcium absorption. ImmunoPterin is currently available in a sample size of 30 capsules for $14.95. Full size 90-capsule bottles are priced at $27.95 and will be offered on the SanRx website before the end of 2012. For user testimonials and to order ImmunoPterin, visit http://www.sanrx.com/immunopterin/.

About SanRx

Based in San Diego, California, SanRx® is the leading developer of immune-supporting compounds based on the naturally-occurring human small molecule "pterin." Preclinical testing by reputable third-party laboratories substantiates that the compounds discovered by SanRx provide a strong potential to support the human immune system against a number of immune imbalance conditions without the side effects or high cost of traditional therapies.

For more information, visit www.sanrx.com.

Company Contact:
Dr Phillip Moheno, SanRx President and Chief Scientist,
phil.moheno@sanrx.com, 858-344-9778.

Media Contact:
Cynthia Jones, Jones & Taylor Communications,
cjcom@cableone.net, 928-273-0513.



SanRx Demonstrates Ability To Boost The Immune System Against Tumors, Diabetes, and TB Developmental Stage Company Seeks Funding to Complete FDA Study

October 6, 2011 – San Diego, CA

SanRx ® announced today that following positive third-party test results of their pterin-based immune system boosting compounds, Pterin+Calcium™ and DCP™, they are seeking funding to comply with a required FDA study.

The pterin-based compounds developed by SanRx have been shown to suggest a strong ability to boost the human immune system against a number of immune imbalance conditions, including cancerous tumors, Hepatitis B, Tuberculosis and most recently Diabetes. "We are extremely pleased by the recent diabetes-study results from the Millipore Corporation (http://www.millipore.com/) and Dr. Dietmar Fuchs, of the Innsbruck Medical University in Austria," commented Dr. Phillip Moheno, SanRx President and Chief Scientist. "We are eager to seize this momentum and move forward on securing FDA approval of Pterin+Calcium as a nutritional supplement," Moheno added.

For more information, visit www.sanrx.com.

Company Contact:
Dr Phillip Moheno, SanRx President and Chief Scientist,
phil.moheno@sanrx.com, 858-344-9778.

Media Contact:
Cynthia Jones, Jones & Taylor Communications,
cjcom@cableone.net, 928-273-0513.






SanRx's DCP™ Shows Promising Results Against Diabetes in Recent Study

February 6th, 2012

SAN DIEGO, CA – February 6th, 2012 – SanRx® announced today that their recent study entitled Effect of Orally Administered Dipterinyl Calcium Pentahydrate (DCP™) on Oral Glucose Tolerance in DIO Mice, was accepted for publication in "Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy" by Dove Medical Press. This work was carried out in collaboration with Dr. Svetlana E. Nikoulina (SanRx) and Dr. Dietmar Fuchs (Innsbruck Medical University, Austria). A copy of the paper can be accessed on the SanRx website under publications. The oral glucose tolerance test is one of the principal tests used in the diagnosis of diabetes.

"This is a significant milestone for SanRx and our research into the use of pterins to fight many of the world's most troubling immune imbalances," commented Dr. Phillip B. Moheno, SanRx President and Chief Scientist. "In addition to the fight against diabetes (projected new cases of 9.1 per 1,000 adults a year in the US), previous research has shown pterins are also valuable in the fight against cancerous tumors, hepatitis B, tuberculosis, and arthritis," added Moheno.

For more information, visit www.sanrx.com.

Company Contact:
Dr Phillip Moheno, SanRx President and Chief Scientist,
phil.moheno@sanrx.com, 858-344-9778.

Media Contact:
Cynthia Jones, Jones & Taylor Communications,
cjcom@cableone.net, 928-273-0513.

In the News

See what the leading industry publications are saying about SanRx:

December 2012

NutraIngredients.USA (December 21, 2012) - Startup launches Immune Support Supplement
http://www.nutraingredients-usa.com/Industry/Startup-launches-immune-support-supplement-based-on-novel-pterin-pathway

Evaluate Pharma (December 17, 2012) - SanRx® Introduces ImmunoPterin™
http://www.evaluatepharma.com/Universal/View.aspx?type=Story&id=371524

San Diego Tech Scene (December 21, 2012) - Startup launches Immune Support Supplement
http://news.sdtechscene.org/2012/12/21/startup-launches-immune-support-supplement-based-on-novel-pterin-pathway-nutraingredients-usa-com/

WittySparks, Technology, Design and Life Tips
http://flair.wittysparks.com/article/0fgH0J94xW4od/startup-launches-immune-support-supplement-based-novel-pterin-pathway

Events

2013

SanRx will be exhibiting at the 2013 OncANP Naturopathic Oncology Conference February 15th-17th, 2013 Arizona Grand Resort & Spa| Phoenix, Arizona
http://www.oncanp.org/2013conference.html

SanRx will be attending the 2013 Natural Products Expo West March 8-10, 2013 Anaheim Convention Center, Anaheim CA
http://www.expowest.com/ew13/public/enter.aspx

2012

SanRx is attending the Cancer Control Society Convention, September 1-3, 2012, Universal City, CA
http://www.cancercontrolsociety.com/meeting2012-html.html

SanRx is presenting at the 2012 WBT Innovation Marketplace in San Diego, CA. October 24 -26, 2012, WBT Innovation Marketplace.
http://www.wbtshowcase.com

SanRx is presenting at the NCN Ingredients & Technology Investor Meeting IV at SupplySide West, Sands Expo & Convention Center, Las Vegas

Tuesday, November 6, 2012, 1:00-5:30 p.m.
http://www.nutritioncapital.com/NCN_at_SupplySide_Fall


Past Events

May 9th-13th, 2011

15th International Symposium of Pteridines and Folates

Website: http://www.pteridinesfolates2012.org/

March 9-11, 2012

SanRx attended Natural Products Expo/Engredea.

October 12th-13th, 2011

SanRx attended the SupplySide West Tradeshow in Las Vegas.

Website: http://www.supplysideshow.com




SanRx was a presenter at NCN's Fall Investor Meeting.

http://www.nutritioncapital.com/

Want to receive updates from us?

Subscribe to our newsletter list by entering your information below.

  • This field is for validation purposes and should be left unchanged.